Kimberly-Clark Corporation (KMB)vsArcadia Biosciences Inc (RKDA)
KMB
Kimberly-Clark Corporation
$98.43
+2.42%
CONSUMER DEFENSIVE · Cap: $31.90B
RKDA
Arcadia Biosciences Inc
$1.05
-0.94%
CONSUMER DEFENSIVE · Cap: $2.20M
Smart Verdict
WallStSmart Research — data-driven comparison
Kimberly-Clark Corporation generates 340699% more annual revenue ($16.56B vs $4.86M). KMB leads profitability with a 12.8% profit margin vs -48.1%. KMB earns a higher WallStSmart Score of 63/100 (C+).
KMB
Buy63
out of 100
Grade: C+
RKDA
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.0%
Fair Value
$90.45
Current Price
$98.43
$7.98 premium
Margin of Safety
+56.6%
Fair Value
$4.01
Current Price
$1.05
$2.96 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 112 in profit
Reasonable price relative to book value
Earnings expanding 28.5% YoY
Areas to Watch
Expensive relative to growth rate
2.7% revenue growth
Weak financial health signals
Trading at 21.7x book value
Smaller company, higher risk/reward
Weak financial health signals
ROE of -45.1% — below average capital efficiency
Revenue declined 25.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : KMB
The strongest argument for KMB centers on Return on Equity.
Bull Case : RKDA
The strongest argument for RKDA centers on Price/Book, EPS Growth.
Bear Case : KMB
The primary concerns for KMB are PEG Ratio, Revenue Growth, Piotroski F-Score. Debt-to-equity of 4.77 is elevated, increasing financial risk.
Bear Case : RKDA
The primary concerns for RKDA are Market Cap, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
KMB profiles as a value stock while RKDA is a turnaround play — different risk/reward profiles.
RKDA carries more volatility with a beta of 0.72 — expect wider price swings.
KMB is growing revenue faster at 2.7% — sustainability is the question.
KMB generates stronger free cash flow (575M), providing more financial flexibility.
Bottom Line
KMB scores higher overall (63/100 vs 37/100). RKDA offers better value entry with a 56.6% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kimberly-Clark Corporation
CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS · USA
Kimberly-Clark Corporation is an American multinational personal care corporation that produces mostly paper-based consumer products. The company manufactures sanitary paper products and surgical & medical instruments. Kimberly-Clark brand name products include Kleenex facial tissue, Kotex feminine hygiene products, Cottonelle, Scott and Andrex toilet paper, Wypall utility wipes, KimWipes scientific cleaning wipes and Huggies disposable diapers and baby wipes.
Visit Website →Arcadia Biosciences Inc
CONSUMER DEFENSIVE · PACKAGED FOODS · USA
Arcadia Biosciences, Inc. is dedicated to developing various crop productivity traits primarily in hemp, wheat, and soybeans. The company is headquartered in Davis, California.
Visit Website →Compare with Other HOUSEHOLD & PERSONAL PRODUCTS Stocks
Want to dig deeper into these stocks?